article thumbnail

Value-Based Health Care Needs All Stakeholders at the Table – Especially the Patient

Health Populi

[Note: I may be biased as a University of Michigan graduate of both the School of Public Health and Rackham School of Graduate Studies in Economics]. health care, patient assistance programs, Medicare Advantage plans, and the bundling of proven high-value preventive services into the Affordable Care Act.

article thumbnail

The Healthcare and Macro-Economic Impacts of Living with Endemic COVID – Listening to Fitch

Health Populi

We also expect innovation to come out of pharma and biotech labs, and who will pay for new-new therapies? For Medicare Part B programs alone, the drug could consume one-half of the total $57 billion of medicines spending… as much as the U.S. spends on NASA.

BioTech 270
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

In U.S. Health Care, It’s Still the Prices, Stupid – But Transparency and Consumer Behavior Aren’t Working As Planned

Health Populi

As the Harvard Chan-POLITICO study points out, prescription drug costs are top-of-mind for health consumers in America. First, a Wall Street Journal profile of Bluebird Bio , a biotech firm that plans to sell gene-replacement therapy extending annual payments to patients based on whether the drug is effective.

BioTech 160
article thumbnail

Will Consumers Cross the Cost-and-Trust Chasm Between Prescription Drugs and Hospitals?

Health Populi

A recent study on politics and health care spending in the U.S. published by the National Bureau of Economic Research found a close link between electoral politics and Medicare: that is, between legislative processes in the U.S. Congress and healthcare spending.

article thumbnail

Prescription Drug Costs In America Through the Patient Lens, via IQVIA, GoodRx and a New $2 Million Therapy

Health Populi

In 2018, we saw more incentives to inspire adherence to prescription drug regimens, particularly in Medicare Part D along with increasing focus by pharmacists and providers. Just under 9% of patients across all three health plan types had over $500 in OOP costs in 2018. A cost of $125 or more yields abandonment of at least 50%.

Medicare 149
article thumbnail

Americans Across Political Party Worry About Prescription Drug Prices – Especially to Deal with COVID-19

Health Populi

The authors, Dr. Naci and Dr. Kesselheim, are affiliated with the London School of Economics and Brigham and Women’s Hospital in Boston, note that 1% of medicines dispensed under Medicare Part D and Medicaid accounted for nearly $1 in $3 of drug spending in each program in 2015. bn to $32.8 bn to $9.9 bn for Medicaid.

BioTech 191
article thumbnail

Prescription Drugs in the Pandemic, Year 2: Pricing Rx and Going Direct-to-Consumer

Health Populi

There is one health care public policy issue that unites U.S. voters across political party: that is the consumer-facing costs of prescription drugs.